This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences practice is dedicated to providing tailored solutions to help maximize value and drive towards equitable access to life-saving treatments.
Financier Worldwide Magazine featured CRA’s Dr. Gregory Bell as an Exceptional Expert in the Power Players report on International Arbitration.
Antimicrobial resistance (AMR) imposes a significant burden on patients facing both acute and chronic infections.
Join CRA and leading European payer experts for a 30-minute virtual webinar as we explore how growing competitive dynamics are reshaping the rare diseases...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
